Investor Spotlight: The Dementia Discovery Fund
JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1
March 15, 2018 from 11:30 AM to 14:00 PM (EST)
$10 - $35
Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.
On March 15th, Barbara Tate, Venture Partner at Dementia Discovery Fund will be in attendance to give an overview presentation about their company's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 28th, 2018. Apply Here.
The Dementia Discovery Fund (“DDF”) is a highly innovative new fund backed by the UK Government, Alzheimer’s Research UK and seven of the world’s leading pharmaceutical and biotech companies. The DDF is funding the discovery and development of new disease-modifying treatments for Alzheimer’s and other forms of dementia with the intent to dramatically improve the quality of life for the growing number of dementia sufferers and their families.
Following the presentation, don't miss this opportunity to introduce yourself to Stefan during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Versant Ventures will provide an intimate forum to discuss your company.
The Centre for Aging + Brain Health Innovation (CABHI), led by Baycrest Health Sciences, is a solution accelerator in aging and brain health. Through a number of programs, up to $500,000 in project funding is available to support the development, testing and validation of innovative products, services and best practices to improve the brain health and quality of life for older adults. Ultimately, CABHI’s vision is a world in which people can age in the setting of their choice, maintaining their cognitive, emotional and physical well-being as well as their independence for as long as possible. Since inception, CABHI has levered over $28 million towards solution acceleration activities, approved and launched over 90 projects, and engaged over 250 partners and collaborators. For information on how you can work with CABHI, email [email protected] .
10:30 AM | Registration and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking and Lunch
12:30 PM - 5:00 PM | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on February 28th, 2018.
$15 | General Public
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on March 14th (or sold out).
JLABS @ Toronto
661 University Ave, Suite 1300
Dementia Discovery Fund Representative:
Barbara Tate, Ph.D | Venture Partner, Dementia Discovery Fund
Dr. Barbara Tate is a neuroscientist who has worked in both large and small pharmaceutical companies. Prior to joining DDF, she was Vice President and Head of Biology at Rodin Therapeutics, an Atlas Venture company, where she also consulted on other portfolio companies. Prior to Rodin, Barbara was Vice President for Research at Satori Pharmaceuticals, a biotech company developing a treatment for Alzheimer’s disease. Barbara also worked at Pfizer, where she managed the neurodegenerative disease area group in Groton, CT.
Prior to working in industry, Barbara was an academic researcher at Brown Medical School and Harvard Medical School. Barbara has a BA in Biology, a PhD in Physiology, and she was a postdoctoral fellow at Harvard Medical School. The Dementia Discovery Fund (“DDF”) is a highly innovative new fund backed by the UK Government, Alzheimer’s Research UK and seven of the world’s leading pharmaceutical and biotech companies. The DDF is funding the discovery and development of new disease-modifying treatments for Alzheimer’s and other forms of dementia with the intent to dramatically improve the quality of life for the growing number of dementia sufferers and their families.
Connect with Barbara: